ibrutinib,zanubrutinib
beigene,abbvie,janssen
['zanubrutinib', 'cll', ' ibru', 'alpine']
there was a lot of media interest for dr. jennifer brown s, md, phd phase 3 alpine study presented at #ash22.
her results found zanubrutinib showed superior efficacy w/fewer side effects than ibrutinib, which could change the standard of care for cll and sll patients. 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090